Inflammation score and Lu-177 treatment for midgut NET
Part of Cancer, Digestive system clinical trials.
This study looks at whether a simple blood test (inflammation score) can predict how well the drug Lu-177 oxodotreotide (Lutathera) will work for people with midgut neuroendocrine tumors that have grown or spread. It may help doctors understand who benefits most from this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a midgut neuroendocrine tumor (NET) that is grade 1 or 2 (low or intermediate grade).
- Your tumor has grown or spread in the last 12 months, based on scans like CT, MRI, or PET.
- You have not had Lu-177 oxodotreotide (Lutathera) treatment before.
- You do not have an active, uncontrolled inflammatory condition (like severe arthritis or inflammatory bowel disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a radioactive drug called Lu177-Dotatate (PRRT) works better than usual care for people with slow-growing, advanced midgut neuroendocrine tumors (NETs). It may help shrink or slow the growth of tumors when you also get somatostatin analog therapy.
This Phase 2 study looks at whether giving Lutathera again (a second round) can control an intestinal neuroendocrine tumor (NET) that came back or progressed after the first treatment. It mainly targets adults whose scan shows tumors still take up the right “target” signal and who previously benefited for at least 12 months.
This phase 3 trial tests a radioactive drug (177Lu-DOTATATE) against a long-acting medication (Octreotide LAR) for people with advanced neuroendocrine tumors (NETs) that have grown despite standard treatment. The study aims to see which treatment works better and is safer.
This trial tests a radioactive drug called Lutetium-177 Oxodotreotide (a type of PRRT) for people with advanced neuroendocrine tumors that have already been treated with other therapies and are still growing. The drug targets somatostatin receptors on tumor cells to deliver radiation directly to the cancer.
This trial tests a personalized way to give a radioactive drug called Lutathera to people with neuroendocrine tumors (NETs). The goal is to see if adjusting the dose based on how your body absorbs it can be more effective.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
Hear when a new Intestinal Neuroendocrine Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.